Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | LOX | P28300 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6493962 | 0.94 | ATM (0.47) | DRD2ATMKDM4ECA2CYP19A1 | |
| SCHEMBL9040112 | 0.92 | DRD2 (0.44) | DRD2ATMKDM4ECA2CYP19A1 | |
| SCHEMBL24541757 | 0.88 | ATM (0.66) | DRD2ATMKDM4ECA2CYP19A1 | |
| SCHEMBL3119147 | 0.84 | DRD2 (0.56) | DRD2ATMKDM4ECA2ALDH1A1 | |
| SCHEMBL29565908 | 0.83 | DRD2 (0.55) | DRD2ATMKDM4ECA2CYP19A1 | |
| SCHEMBL1635299 | 0.83 | DRD2 (0.51) | DRD2ATMKDM4ECA2CYP19A1 | |
| SCHEMBL21752810 | 0.83 | DRD2 (0.38) | DRD2ATMKDM4ELOXLOXL2 | |
| SCHEMBL6138549 | 0.82 | DRD2 (0.54) | DRD2ATMKDM4ECA2ALDH1A1 | |
| SCHEMBL30038388 | 0.81 | DRD2 (0.50) | DRD2ATMKDM4ECA2CYP19A1 | |
| Bromide SCHEMBL5608443 | 0.80 | DRD2 (0.49) | DRD2ATMKDM4ECA2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536174-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-8536174-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | disclosed |
| US-8193191-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-05 | — | — | US | disclosed |
| US-20110136824-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E | 2011-06-09 | — | — | US | disclosed |
| US-7915260-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-03-29 | — | — | US | disclosed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| US-6818638-B2 | LACTONE RING IS MODIFIED; PREVENTING OR TREATING DISORDERS MEDIATED BY LFA-1/ ICAM-1 INTERACTIONS. | NOVARTIS AG (CH) | 2004-11-16 | — | — | US | disclosed |
| EP-1154988-B1 | MEVINOLIN DERIVATIVES | NOVARTIS AG (CH) | 2004-08-11 | — | — | EP | disclosed |
| US-20030087903-A1 | Mevinolin derivatives | NOVARTIS AG (CH) | 2003-05-08 | — | — | US | disclosed |
| US-20020037895-A1 | Mevinolin derivatives | BAENTELI ROLF (CH) | 2002-03-28 | — | — | US | disclosed |
| EP-1154988-A1 | MEVINOLIN DERIVATIVES | Novartis AG (CH) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000048989-A1 | MEVINOLIN DERIVATIVES | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, BDKRB2 | DRD2 1354/4885ATM 4730/4885KDM4E 4555/4885 |
| US-20070191391-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, BDKRB2 | DRD2 1354/4885ATM 4730/4885KDM4E 4555/4885 |
| US-20020037895-A1 | Mevinolin derivatives | ICAM1, VCAM1, EPCAM | DRD2 3572/4885ATM 1224/4885KDM4E 2705/4885 |
| US-20030087903-A1 | Mevinolin derivatives | ICAM1, VCAM1, EPCAM | DRD2 3572/4885ATM 1224/4885KDM4E 2705/4885 |
| US-20110136824-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, BDKRB2 | DRD2 1354/4885ATM 4730/4885KDM4E 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.